PMA device
GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
W. L. Gore & Associates, Inc. · System, Endovascular Graft, Arteriovenous (Av) Dialysis Access Circuit Stenosis Treatment (PFV, Class III) · First FDA decision Dec 5, 2013, newest May 26, 2022Kidney failure and dialysisVascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
7
PMA pathway
Device trials
30
Naming "GORE VIABAHN Endoprosthesis"
MAUDE reports
385
Brand "GORE VIABAHN Endoprosthesis", since 2015
PubMed studies
26
Mentioning "GORE VIABAHN Endoprosthesis"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 7 decisions filed under this name.
P130006-S091 · Decided May 26, 2022 · 101 days after receipt · Normal 180 Day Track No User Fee
Device type: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV) · Cardiology
- GORE VIABAHN Endoprosthesis product family and GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface product familyPMA supplement
P130006-S082 · Decided Aug 2, 2021 · 164 days after receipt · Normal 180 Day Track No User Fee
Device type: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV) · Cardiology
- GORE VIABAHN Endoprosthesis product family abd GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface product familyPMA supplement
P130006-S073 · Decided Feb 28, 2020 · 178 days after receipt · Normal 180 Day Track No User Fee
Device type: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment (PFV) · Cardiology
3 more FDA decisions with a free account
Older decisions: P130006
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Hemodialysis for Treatment of SchizophreniaNational determinationOn the books130.8Updated Dec 2, 2002
- Dialysis Access MaintenanceLocal determinationIn effectL34062CGS Administrators, LLCUpdated Feb 20, 2026
- Non-Invasive Peripheral Venous Vascular and Hemodialysis Access StudiesLocal determinationIn effectL35751WPS Insurance CorporationUpdated Feb 20, 2026
- Application of Skin Substitute Grafts for Treatment of DFU and VLU of Lower ExtremitiesLocal determinationIn effectL36377First Coast Service Options, Inc.Updated Nov 21, 2019
Clinical trials
Device studies on ClinicalTrials.gov that name "GORE VIABAHN Endoprosthesis", any status and sponsor, newest update first.
W.L.Gore & AssociatesNot on our public-company list
NCT06872905 · 158 participants (planned) · Start May 30, 2025 · Primary completion Aug 16, 2027
Device: GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX) · For: Aortoiliac Occlusive Disease
Sites: Birmingham, Alabama; Fresno, California; Tampa, Florida · 27 sites in all
W.L.Gore & AssociatesNot on our public-company list
NCT05143138 · 259 participants · Start Mar 23, 2022 · Primary completion Apr 30, 2024
Device: GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis · For: Abdominal Aortic Aneurysm; Thoracic Aortic Aneurysm
Sites: Aarhus, Denmark; Copenhagen, Denmark; Genova, Italy · 14 sites in all
- Laser In Situ Fenestration StudyRecruiting
Jonathan BathAcademic, hospital or other
NCT06411990 · 15 participants (planned) · Start Oct 15, 2024 · Primary completion Jun 2028
Device: Fenestrated Endovascular Aneurysm Repair using the LIFE Device System · For: Aortic Aneurysm; Endovascular Aneurysm Repair
Sites: Columbia, Missouri
27 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "GORE VIABAHN Endoprosthesis", and for the whole product code for context.
This brand
385 reports: 106 malfunction, 270 injury, 8 death
Whole product code PFV
2,805 reports: 1,911 malfunction, 863 injury, 31 death
Newest reports for this brand
- GORE VIABAHN ENDOPROSTHESIS WITH HEPARINMalfunction
23989659 · Received Jan 7, 2026 · Event dated Mar 31, 2025
Device type: Stent, Superficial Femoral Artery (NIP)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- GORE VIABAHN ENDOPROSTHESIS WITH HEPARINMalfunction
20842148 · Received Dec 4, 2024 · Event dated Nov 21, 2024
Device type: Stent, Superficial Femoral Artery (NIP)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- GORE VIABAHN ENDOPROSTHESIS WITH HEPARINMalfunction
20694041 · Received Nov 15, 2024 · Event dated Oct 10, 2024
Device type: System, Endovascular Graft, Arteriovenous (Av) Dialysis Access Circuit Stenosis Treatment (PFV)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "GORE VIABAHN Endoprosthesis"[tiab]. The summary above synthesizes these.
- Three-Year Results of the GORE VIABAHN Endoprosthesis in the Superficial Femoral Artery for In-Stent Restenosis.
Soukas P, Becker M, Stark K, et al. · J Soc Cardiovasc Angiogr Interv · 2023
- Five-year outcomes of the GORE VIABAHN Endoprosthesis for the treatment of complex femoropopliteal lesions from a Japanese postmarket surveillance study.
Iida O, Ohki T, Soga Y, et al. · Vasc Med · 2024Multicenter Study, Observational Study
- Erratum: Three-Year Results of the GORE VIABAHN Endoprosthesis in the Superficial Femoral Artery for In-Stent Restenosis.
Soukas P, Becker M, Stark K, et al. · J Soc Cardiovasc Angiogr Interv · 2023Published Erratum
- A Very Rare Cause of Thrombotic Peripheral Occlusion.
Kretzschmar D, Thieme M, Aschenbach R, et al. · Int J Angiol · 2023Case Reports
- Adherence to instruction for use after endovascular repair of popliteal artery aneurysm.
Wrede A, Lehti L, Eiberg JP, et al. · Vascular · 2022
- Evaluation of Femoropopliteal In-Stent Restenosis Characteristics Stratified by Stent Design.
Noory E, Böhme T, Salm J, et al. · J Clin Med · 2023
- Laser Atherectomy and Restenting of the Superficial Femoral Artery Using GORE VIABAHN Endoprosthesis Following Failure of Both Bare-Metal Stenting and Surgical Revascularization.
Khawer A, Diaz CF · Case Rep Vasc Med · 2024Case Reports
- One-Year Clinical Outcomes of a Self-Expanding Covered Stent for Aortoiliac Occlusive Disease.
Reijnen MMPJ, Mezes P, Tigkiropoulos K · J Endovasc Ther · 2025
- Individual Patient Data Meta-Analysis of GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface for Treatment of Femoro-Popliteal Arterial Disease (INSIGHT VSX).
Wetzels H, Holewijn S, Zomer S, et al. · J Endovasc Ther · 2026
- Treatment with a self-expanding endoprosthesis in patients with stenosis or occlusion at the arteriovenous graft: 6-Month outcomes of a post-marketing surveillance study.
Haruguchi H, Fukasawa M, Ikeda K, et al. · J Vasc Access · 2025Multicenter Study
- Interventional repair of a vascular aneurysm in a patient with Marfan syndrome.
Ghonem ME, Yuan X, Mitsis A, et al. · SAGE Open Med Case Rep · 2018Case Reports
- Stent-grafts are the best way to treat complex in-stent restenosis lesions in the superficial femoral artery: 24-month results from a multicenter randomized trial.
Bosiers M, Deloose K, Callaert J, et al. · J Cardiovasc Surg (Torino) · 2020Multicenter Study, Randomized Controlled Trial
Other devices of this type
Also filed under product code PFV.
- Covera Vascular Covered StentC.R. Bard, Inc. · PMA 2022
- WRAPSODY® Cell-Impermeable EndoprosthesisMerit Medical Systems, Inc. · PMA 2025
- Fluency Plus Endovascular Stent GraftBard Peripheral Vascular, Inc. · PMA 2017
- Flair Endovascular Stent GraftBard Peripheral Vascular · PMA 2014
- Bard Flair Endovascular Stent GraftBard Peripheral Vascular · PMA 2010
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.